2023 World Conference on Lung Cancer (Posters)-EP17.03. Utilities Used in HTAs in mNSCLC Following Progression on or After Platinum-Based Chemotherapy

Pdf Summary

This study reviewed 17 health technology assessments (HTAs) conducted between 2015 and 2018 in Europe and North America to assess the patient-reported outcomes (PRO) of treatments for metastatic non-small cell lung cancer (mNSCLC) following progression on or after platinum-based chemotherapy. The treatments assessed included nivolumab, pembrolizumab, atezolizumab, and nintedanib/docetaxel. The PRO reported in these HTAs were derived from EuroQol-5D (EQ-5D) utility data collected from the pivotal trials of the respective treatments.<br /><br />The study found that there was a higher usage of health state utility values (HSUVs) based on EQ-5D data collected from pivotal trials in the HTAs. However, methodologies including mapping algorithms are available to estimate EQ-5D utility values. The careful estimation of HSUVs is important as it is a critical input parameter for cost-utility analyses and value assessment of novel treatments for patients with platinum-resistant mNSCLC.<br /><br />Over 100 utility estimates were used in the 17 HTAs, and these estimates were derived from patients segmented by time, treatment, programmed death-ligand 1 (PD-L1) status, time-to-death, disease progression status, or a combination of these factors. The mean HSUV estimate was .662 (.124) and the median estimate was .681 (.284, .879). The minimum observed utility estimates corresponded to less than 30 days to death, while the maximum estimates corresponded to greater than a year from death.<br /><br />It is worth noting that this study was funded by Novocure Inc., and the PRO information was gathered from HTA organizations in England, Canada, France, Sweden, and the United States. Additionally, HSUVs for HTAs from Canada, Sweden, and France were weighted based on country-specific data. Overall, the study highlights the importance of careful consideration when estimating HSUVs in cost-utility analyses and value assessments for patients with platinum-resistant mNSCLC.

Asset Subtitle

Cloe Ying Chee Koh

Meta Tag

Speaker Cloe Ying Chee Koh

Topic Global Health, Health Services & Health Economics: Health Economics

Keywords

health technology assessments

patient-reported outcomes

metastatic non-small cell lung cancer

platinum-based chemotherapy

EuroQol-5D

health state utility values

cost-utility analyses

platinum-resistant mNSCLC

utility estimates

HTA organizations